US Stock Movement: Oruka Therapeutics surged on October 20; BTIG reiterated Buy rating and released ORKA-001 clinical data

Oruka Therapeutics October 20 Surge Analysis

Keywords: BTIG reaffirms Buy, ORKA-001 clinical data

1. On October 19, BTIG reaffirmed its "Buy" rating on Oruka Therapeutics and maintained a target price of $151; analysts referenced the clinical data of ORKA-001.

2. On September 23, the company announced the week 28 results of the EVERLAST-A Phase IIa trial: the PASI 100 response rate in the ORKA-001 group was 71.4%, and the PASI 90 response rate was 87.3%, with no additional dosing after week 4.

(Disclaimer: This content is generated by AI technology by summarizing publicly available information and is for reference only. It does not constitute investment advice.)